Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL 1 /VLDL 2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
Bruno Vergès, Alexia Rouland, Benjamin Bouillet et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of dapagliflozin on lipid metabolism in 24 individuals with type 2 diabetes. After 6 months of treatment, dapagliflozin did not significantly alter LDL catabolism or levels of LDL-cholesterol and ApoB100. However, it significantly reduced direct catabolism of VLDL 1 and increased its indirect catabolism towards VLDL 2 and IDL, indicating a shift towards more normal lipid metabolism.
Key findings
- Dapagliflozin treatment resulted in a significant reduction in body weight (p<0.001) and HbA1c (p=0.001).
- LDL-ApoB100 fractional catabolism remained unchanged after treatment (0.88 ± 0.37 vs 0.79 ± 0.31 pool/day, p=0.16).
- Direct catabolism of VLDL 1-ApoB100 decreased significantly (0.33 ± 0.65 vs 2.37 ± 2.31 pool/day, p=0.001).
- Indirect catabolism of VLDL 1 towards VLDL 2 and IDL increased significantly (2.71 ± 1.51 vs 1.68 ± 1.46 pool/day, p=0.001).
Why it matters
Understanding the effects of SGLT2 inhibitors like dapagliflozin on lipid metabolism is crucial, as it may influence cardiovascular risk management in patients with type 2 diabetes. This study suggests that dapagliflozin does not impair LDL metabolism, which is important for clinicians considering its use.